The READY trial is a clinical research trial of an investigational drug for metastatic prostate cancer.
The goal of the READY trial is to evaluate the safety and efficacy of the investigational drug (dasatinib) in combination with the standard of care (docetaxel) vs docetaxel alone in patients with metastatic prostate cancer.
The READY clinical research trial is currently enrolling participants. Approximately 1,650 men are expected to participate in the trial at more than 175 sites globally.
Please select the appropriate trial information to learn more.